Movatterモバイル変換


[0]ホーム

URL:


SG10201601913RA - Yeast-brachyury immunotherapeutic compositions - Google Patents

Yeast-brachyury immunotherapeutic compositions

Info

Publication number
SG10201601913RA
SG10201601913RASG10201601913RASG10201601913RASG10201601913RASG 10201601913R ASG10201601913R ASG 10201601913RASG 10201601913R ASG10201601913R ASG 10201601913RASG 10201601913R ASG10201601913R ASG 10201601913RASG 10201601913R ASG10201601913R ASG 10201601913RA
Authority
SG
Singapore
Prior art keywords
yeast
immunotherapeutic compositions
brachyury immunotherapeutic
brachyury
compositions
Prior art date
Application number
SG10201601913RA
Inventor
Claudia Palena
Zhimin Guo
David Apelian
Jeffrey Schlom
Original Assignee
Globeimmune Inc
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Globeimmune Inc, Us HealthfiledCriticalGlobeimmune Inc
Publication of SG10201601913RApublicationCriticalpatent/SG10201601913RA/en

Links

Classifications

Landscapes

SG10201601913RA2011-03-172012-03-19Yeast-brachyury immunotherapeutic compositionsSG10201601913RA (en)

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
US201161453656P2011-03-172011-03-17

Publications (1)

Publication NumberPublication Date
SG10201601913RAtrue SG10201601913RA (en)2016-05-30

Family

ID=46831122

Family Applications (2)

Application NumberTitlePriority DateFiling Date
SG10201601913RASG10201601913RA (en)2011-03-172012-03-19Yeast-brachyury immunotherapeutic compositions
SG2013068176ASG193396A1 (en)2011-03-172012-03-19Yeast-brachyury immunotherapeutic compositions

Family Applications After (1)

Application NumberTitlePriority DateFiling Date
SG2013068176ASG193396A1 (en)2011-03-172012-03-19Yeast-brachyury immunotherapeutic compositions

Country Status (19)

CountryLink
US (5)US9198941B2 (en)
EP (2)EP3238731B1 (en)
JP (4)JP6068368B2 (en)
KR (1)KR102046449B1 (en)
CN (1)CN103648513B (en)
AU (3)AU2012228937B2 (en)
BR (1)BR112013023456B1 (en)
CA (1)CA2835475C (en)
DK (1)DK2685995T3 (en)
ES (1)ES2627979T3 (en)
HK (1)HK1245649A1 (en)
HU (1)HUE033491T2 (en)
IL (1)IL228421B (en)
MX (1)MX350661B (en)
PL (1)PL2685995T3 (en)
PT (1)PT2685995T (en)
RU (2)RU2690180C2 (en)
SG (2)SG10201601913RA (en)
WO (1)WO2012125998A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
EP3539567A1 (en)2007-07-022019-09-18Etubics CorporationMethods and compositions for producing an adenovirus vector for use with multiple vaccinations
ES2696551T3 (en)2010-12-172019-01-16Globeimmune Inc Compositions and methods for the treatment or prevention of human adenovirus-36 infection
JP5745102B2 (en)2011-02-122015-07-08グローブイミューン,インコーポレイテッド Yeast-based immunotherapy composition for chronic hepatitis B infection
MX350661B (en)2011-03-172017-09-13Us Health IMMUNOTHERAPEUTIC COMPOSITIONS OF LEVADURA-BRACHYURI.
WO2012174220A1 (en)2011-06-142012-12-20Globeimmune, Inc.Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection
CN104024429B (en)2011-08-172019-06-04全球免疫股份有限公司 Yeast-MUC1 immunotherapy composition and use thereof
SG11201408652SA (en)2012-06-262015-01-29Biodesix IncMass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
WO2014031178A1 (en)2012-08-242014-02-27Etubics CorporationReplication defective adenovirus vector in vaccination
ES2752190T3 (en)2012-09-142020-04-03Us Health Brachyury protein, adenoviral vectors encoding Brachyury protein and their use
US10507235B2 (en)*2013-03-192019-12-17Globeimmune, Inc.Yeast-based immunotherapy for Chordoma
TWI626948B (en)2013-03-262018-06-21環球免疫公司Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
US9725494B2 (en)*2013-05-172017-08-08United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesSoluble CD27 (sCD27) and the use thereof
WO2015031778A2 (en)2013-08-302015-03-05Globeimmune, Inc.Compositions and methods for the treatment or prevention of tuberculosis
CN106456677B (en)2014-04-112025-06-03全球免疫股份有限公司 Yeast-based immunotherapy and type I interferon sensitivity
CA2974237C (en)2015-01-092021-07-20Etubics CorporationMethods and compositions for combination immunotherapy
EP3286213B1 (en)2015-04-202021-08-04Etubics CorporationMethods and compositions for combination immunotherapy
AU2016302237B2 (en)2015-08-032022-08-04The United States Of America, As Represented By The Secretary Department Of Health And Human ServicesBrachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use
CA2994272C (en)*2015-08-032023-08-22Globeimmune, Inc.Modified yeast-brachyury immunotherapeutic compositions
AU2017281126A1 (en)2016-03-242018-10-04Nant Holdings Ip, LlcSequence arrangements and sequences for neoepitope presentation
EP3463450A4 (en)*2016-06-032020-07-29Etubics Corporation COMPOSITIONS AND METHODS FOR TUMOR VACCINATION WITH PROSTATE CANCER-ASSOCIATED ANTIGENS
EP3541400B1 (en)*2016-11-182025-05-14Sanford Burnham Prebys Medical Discovery InstituteGut microbiota and treatment of cancer
KR102306403B1 (en)2017-04-242021-09-28난트셀, 인크. TARGETED NEOEPITOPE VECTORS AND METHODS THEREFOR
US11510982B2 (en)*2017-08-152022-11-29Nantcell, Inc.HaNK cetuximab combinations and methods
WO2019222073A1 (en)2018-05-152019-11-21Globeimmune, Inc.Lysates of recombinant yeast for inducing cellular immune responses
US12285480B2 (en)2020-03-112025-04-29Nantcell, Inc.Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses
US20210284716A1 (en)2020-03-112021-09-16Immunitybio, Inc.ACE2-Fc Trap
US11857620B2 (en)2020-03-112024-01-02Immunitybio, Inc.Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
WO2022178218A1 (en)2021-02-192022-08-25Mevion Medical Systems, Inc.Gantry for a particle therapy system

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US1036329A (en)1908-11-191912-08-20Edison Inc Thomas APhonograph-reproducer.
FR2486400B1 (en)1980-07-091986-05-30Univablot MEDICINAL PRODUCTS BASED ON YEAST OR THEIR INSOLUBLE EXTRACTS
NZ199722A (en)1981-02-251985-12-13Genentech IncDna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4775622A (en)1982-03-081988-10-04Genentech, Inc.Expression, processing and secretion of heterologous protein by yeast
US5310654A (en)1985-07-311994-05-10The Board Of Trustees Of The Leland Stanford Junior UniversityMethod for determining virulence of Yersinia
US5234830A (en)1988-02-031993-08-10Suntory LimitedDNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region
IL95019A0 (en)1989-08-091991-06-10Mycogen CorpProcess for encapsulation of biologicals
US5830463A (en)1993-07-071998-11-03University Technology CorporationYeast-based delivery vehicles
US5413914A (en)1993-07-071995-05-09The Regents Of The University Of ColoradoYeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US5858378A (en)1996-05-021999-01-12Galagen, Inc.Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
US20020044948A1 (en)2000-03-152002-04-18Samir KhleifMethods and compositions for co-stimulation of immunological responses to peptide antigens
EP1272213B1 (en)2000-04-062006-03-08SEER Pharmaceuticals, LLC.Microbial delivery system
US7083787B2 (en)2000-11-152006-08-01Globeimmune, Inc.Yeast-dendritic cell vaccines and uses thereof
EP2630969B1 (en)2002-12-162018-04-11GlobeImmune, Inc.Yeast-based vaccines as immunotherapy
US7439042B2 (en)2002-12-162008-10-21Globeimmune, Inc.Yeast-based therapeutic for chronic hepatitis C infection
CA2614884A1 (en)2005-07-112007-01-18Globeimmune, IncCompositions and methods for eliciting an immune response to escape mutants of targeted therapies
US20070172503A1 (en)2005-12-132007-07-26Mycologics,Inc.Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
CN101405026B (en)*2006-02-022015-04-22全球免疫股份有限公司 Yeast-based vaccines for inducing immune responses
SG170763A1 (en)2006-03-272011-05-30Globeimmune IncRas mutation and compositions and methods related thereto
EP2121013B1 (en)*2007-02-022014-10-15Globeimmune, Inc.Methods for producing yeast-based vaccines
EP2918598B1 (en)2007-02-282019-01-30The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human ServicesBrachyury polypeptides and methods for use
NZ580444A (en)2007-03-192012-02-24Globeimmune IncCompositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
WO2009042645A2 (en)2007-09-242009-04-02President And Fellows Of Harvard CollegeThe use of mice predisposed to develop ulcerative colitis and colon cancer to develop metabolic profiles associated with same
WO2010033841A1 (en)2008-09-192010-03-25Globeimmune, Inc.Immunotherapy for chronic hepatitis c virus infection
WO2010065626A1 (en)2008-12-022010-06-10Globeimmune, Inc.Genotyping tools, methods and kits
US10383924B2 (en)*2009-04-172019-08-20Globeimmune, Inc.Combination immunotherapy compositions against cancer and methods
WO2011032119A1 (en)2009-09-142011-03-17The Regents Of The University Of ColoradoModulation of yeast-based immunotherapy products and responses
WO2011115914A1 (en)2010-03-142011-09-22Globeimmune, Inc.Pharmacogenomic and response-guided treatment of infectious disease using yeast-based immunotherapy
WO2012019127A2 (en)*2010-08-052012-02-09The Regents Of The University Of ColoradoCombination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases
ES2696551T3 (en)2010-12-172019-01-16Globeimmune Inc Compositions and methods for the treatment or prevention of human adenovirus-36 infection
JP5745102B2 (en)2011-02-122015-07-08グローブイミューン,インコーポレイテッド Yeast-based immunotherapy composition for chronic hepatitis B infection
MX350661B (en)2011-03-172017-09-13Us Health IMMUNOTHERAPEUTIC COMPOSITIONS OF LEVADURA-BRACHYURI.
WO2012174220A1 (en)2011-06-142012-12-20Globeimmune, Inc.Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection
CN104024429B (en)2011-08-172019-06-04全球免疫股份有限公司 Yeast-MUC1 immunotherapy composition and use thereof

Also Published As

Publication numberPublication date
BR112013023456A2 (en)2016-12-06
KR102046449B1 (en)2019-11-19
US9198941B2 (en)2015-12-01
MX350661B (en)2017-09-13
CN103648513B (en)2018-10-12
US20190374624A1 (en)2019-12-12
NZ616696A (en)2015-09-25
JP2018090634A (en)2018-06-14
AU2018202972B2 (en)2019-08-29
PL2685995T3 (en)2017-10-31
RU2619850C2 (en)2017-05-18
EP2685995B1 (en)2017-05-03
RU2017116350A (en)2018-10-17
EP2685995A1 (en)2014-01-22
AU2017200715B2 (en)2018-05-31
JP2017061570A (en)2017-03-30
PT2685995T (en)2017-08-09
AU2012228937B2 (en)2016-11-03
US20210106666A1 (en)2021-04-15
CA2835475A1 (en)2012-09-20
CA2835475C (en)2020-06-30
US11944673B2 (en)2024-04-02
IL228421B (en)2019-02-28
ES2627979T3 (en)2017-08-01
JP6309607B2 (en)2018-04-11
US20160106824A1 (en)2016-04-21
JP2014509595A (en)2014-04-21
EP3238731A1 (en)2017-11-01
RU2017116350A3 (en)2018-10-17
IL228421A0 (en)2013-12-31
US20140004135A1 (en)2014-01-02
US9623097B2 (en)2017-04-18
JP2019199484A (en)2019-11-21
HK1245649A1 (en)2018-08-31
RU2013146324A (en)2015-04-27
MX2013010475A (en)2014-05-28
EP2685995A4 (en)2014-12-24
US20170246276A1 (en)2017-08-31
KR20140038387A (en)2014-03-28
US11938175B2 (en)2024-03-26
AU2018202972A1 (en)2018-05-17
BR112013023456B1 (en)2020-11-17
WO2012125998A1 (en)2012-09-20
CN103648513A (en)2014-03-19
DK2685995T3 (en)2017-08-21
HUE033491T2 (en)2017-12-28
EP3238731B1 (en)2021-02-17
SG193396A1 (en)2013-10-30
AU2012228937A1 (en)2013-10-31
JP6068368B2 (en)2017-01-25
AU2017200715A1 (en)2017-02-23
RU2690180C2 (en)2019-05-31
JP6580733B2 (en)2019-09-25
US10363294B2 (en)2019-07-30

Similar Documents

PublicationPublication DateTitle
IL228421A0 (en)Yeast-brachyury immunotherapeutic compositions
ZA201404448B (en)Peracid-generating compositions
IL230863A0 (en)Yeast-muc1 immunotherapeutic compositions and uses thereof
ZA201400330B (en)Novel composition
GB201117619D0 (en)Compositions
SG11201401335QA (en)Compositions
GB201117621D0 (en)Compositions
GB2496447B (en)Compositions
GB201110833D0 (en)Compositions
RS57995B1 (en)Composition
EP2702100A4 (en)Insulation compositions
GB201103942D0 (en)Compositions
GB201110132D0 (en)compositions
GB201104849D0 (en)Compositions
GB201121300D0 (en)Novel composition
GB201114930D0 (en)Novel compositions
GB201108810D0 (en)Novel compositions
GB201122216D0 (en)Compositions
GB201122214D0 (en)Compositions
GB201122213D0 (en)Compositions
GB201121028D0 (en)Compositions
GB201120406D0 (en)Compositions
GB201117234D0 (en)Compositions
GB201117165D0 (en)Compositions
GB201114629D0 (en)Compositions

[8]ページ先頭

©2009-2025 Movatter.jp